ZYDUS LIFESCIENCES Latest Share Price (ZYDUSLIFE)
TODAY IN ONE LINE
ZYDUSLIFE fell 2.0% on light volume, lagging Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹1.12 L Cr., it trades at a P/E of 25.62. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ZYDUS LIFESCIENCES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 179.1% and Profit up 191.6%
- ●Strong Return on EquityHealthy ROE of 17.3%
- ●Healthy Operating MarginsOPM is structurally strong at 26.0%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest ZYDUS LIFESCIENCES News
What changed recently?
Recent events, corporate actions, and announcements.
ZYDUS LIFESCIENCES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ZYDUS LIFESCIENCES, framed against the sector median so the premium or discount is obvious at a glance.
ZYDUS LIFESCIENCES trades at a P/E of 25.62× and P/B of 4.27×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ZYDUS LIFESCIENCES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ZYDUS LIFESCIENCES — derived from the latest tape, not yesterday's close.
ZYDUS LIFESCIENCES last traded at ₹1,120 with an intraday range of ₹1,120–₹1,146 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1120.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1189.33 | +69.33 | +6.19% |
| R3 | 1163.33 | +43.33 | +3.87% |
| R2 | 1154.67 | +34.67 | +3.10% |
| R1 | 1137.33 | +17.33 | +1.55% |
| PIVOT | 1128.67 | 8.67 | 0.77% |
| CURRENT | 1120.00 | — | — |
| S1 | 1111.33 | -8.67 | -0.77% |
| S2 | 1102.67 | -17.33 | -1.55% |
| S3 | 1085.33 | -34.67 | -3.10% |
| S4 | 1059.33 | -60.67 | -5.42% |
ZYDUSLIFE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1128–₹1146
Trading Below opening range, showing Bearishness
ZYDUS LIFESCIENCES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ZYDUS LIFESCIENCES — consolidated or standalone — with margins, YoY growth and key ratios inline.
ZYDUS LIFESCIENCES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.12 L Cr. and reported EPS of ₹9.42.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 23,242 | 27,148 ▲ 16.8% |
| Sales Growth YoY %Derived | 18.90% | 16.81% |
| Other Income | 270 | 510 ▲ 89.1% |
| Total Income | 23,511 | 27,658 ▲ 17.6% |
| 6,338 | 7,293 ▲ 15.1% | |
| Gross ProfitDerived | 16,904 | 19,856 ▲ 17.5% |
| Gross Margin %Derived | 72.73% | 73.14% |
| 9,845 | 11,381 ▲ 15.6% | |
| EBITDA (Operating Profit)Derived | 7,059 | 8,475 ▲ 20.1% |
| OPM %Derived | 30.37% | 31.22% |
| 862 | 1,330 ▲ 54.3% | |
| Profit Before Tax (PBT) | 6,027 | 6,621 ▲ 9.9% |
| 1,412 | 1,595 ▲ 12.9% | |
| Effective Tax %Derived | 23.43% | 24.09% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 4,673 | 5,124 ▲ 9.6% |
| Less: Non-controlling Interests | 4,526 | 84 ▼ 98.2% |
| Net Profit (Owner's PAT)Derived | 147 | 5,040 ▲ 3326.2% |
| Net Profit Margin %Derived | 0.63% | 18.56% |
| PAT Growth YoY %Derived | 29.83% | 3,326.24% |
| Earnings Per Share (EPS ₹) | 1.46 | 50.09 ▲ 3330.8% |
| Diluted Shares Outstanding (Cr) | 101 | 101 ▲ 0.0% |
| Share of Profit from Associates/JVs | 58 | 97 ▲ 68.0% |
| Other Comprehensive Income (Net of Tax) | -100 | -775 ▼ 674.8% |
| Total Expenses (incl. D&A & Interest) | 17,484 | 21,037 ▲ 20.3% |
| Material Cost % of RevenueDerived | 18.82% | 18.82% |
| Employee Cost % of RevenueDerived | 15.84% | 16.27% |
| Other Cost % of RevenueDerived | 26.52% | 25.65% |
| Interest Coverage (x)Derived | 37.03x | 16.10x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 11,936 | 13,166 ▲ 10.3% | 14,253 ▲ 8.3% | 15,102 ▲ 6.0% | 15,265 ▲ 1.1% | 17,237 ▲ 12.9% | 19,547 ▲ 13.4% | 23,242 ▲ 18.9% | 27,148 ▲ 16.8% | |
| Sales Growth YoY %Derived | — | 10.30% | 8.26% | 5.96% | 1.08% | 12.92% | 13.40% | 18.90% | 16.81% | |
| Other Income | 113 | 201 ▲ 77.7% | 114 ▼ 43.4% | 37 ▼ 67.3% | 225 ▲ 504.0% | 187 ▼ 17.0% | 284 ▲ 52.3% | 270 ▼ 5.1% | 510 ▲ 89.1% | |
| Total Income | 12,050 | 13,367 ▲ 10.9% | 14,367 ▲ 7.5% | 15,139 ▲ 5.4% | 15,490 ▲ 2.3% | 17,424 ▲ 12.5% | 19,832 ▲ 13.8% | 23,511 ▲ 18.6% | 27,658 ▲ 17.6% | |
4,154 | 4,716 ▲ 13.6% | 4,920 ▲ 4.3% | 5,210 ▲ 5.9% | 5,545 ▲ 6.4% | 6,310 ▲ 13.8% | 6,228 ▼ 1.3% | 6,338 ▲ 1.8% | 7,293 ▲ 15.1% | ||
| Gross ProfitDerived | 7,783 | 8,449 ▲ 8.6% | 9,333 ▲ 10.5% | 9,892 ▲ 6.0% | 9,720 ▼ 1.7% | 10,927 ▲ 12.4% | 13,319 ▲ 21.9% | 16,904 ▲ 26.9% | 19,856 ▲ 17.5% | |
| Gross Margin %Derived | 65.20% | 64.18% | 65.48% | 65.50% | 63.67% | 63.39% | 68.14% | 72.73% | 73.14% | |
4,935 | 5,476 ▲ 11.0% | 6,550 ▲ 19.6% | 6,551 ▲ 0.0% | 6,379 ▼ 2.6% | 7,067 ▲ 10.8% | 7,935 ▲ 12.3% | 9,845 ▲ 24.1% | 11,381 ▲ 15.6% | ||
| EBITDA (Operating Profit)Derived | 2,848 | 2,973 ▲ 4.4% | 2,783 ▼ 6.4% | 3,341 ▲ 20.0% | 3,341 ▼ 0.0% | 3,860 ▲ 15.5% | 5,384 ▲ 39.5% | 7,059 ▲ 31.1% | 8,475 ▲ 20.1% | |
| OPM %Derived | 23.86% | 22.58% | 19.53% | 22.12% | 21.88% | 22.39% | 27.54% | 30.37% | 31.22% | |
630 | 792 ▲ 25.8% | 675 ▼ 14.8% | 683 ▲ 1.3% | 953 ▲ 39.4% | 248 ▼ 73.9% | 831 ▲ 234.6% | 862 ▲ 3.7% | 1,330 ▲ 54.3% | ||
| Profit Before Tax (PBT) | 2,331 | 2,382 ▲ 2.2% | 1,495 ▼ 37.2% | 2,285 ▲ 52.8% | 2,838 ▲ 24.2% | 2,590 ▼ 8.8% | 4,809 ▲ 85.7% | 6,027 ▲ 25.3% | 6,621 ▲ 9.9% | |
564 | 530 ▼ 6.0% | 320 ▼ 39.7% | 147 ▼ 54.0% | 512 ▲ 247.6% | 588 ▲ 14.9% | 978 ▲ 66.3% | 1,412 ▲ 44.4% | 1,595 ▲ 12.9% | ||
| Effective Tax %Derived | 24.21% | 22.26% | 21.39% | 6.44% | 18.03% | 22.70% | 20.33% | 23.43% | 24.09% | |
| Profit/Loss from Discontinued Ops | -19 | — ▲ 100.0% | — | — | 2,246 | -5 ▼ 100.2% | 23 ▲ 600.0% | — ▼ 100.0% | — | |
| Total Profit for Period | 1,810 | 1,899 ▲ 4.9% | 1,204 ▼ 36.6% | 2,185 ▲ 81.4% | 4,618 ▲ 111.4% | 2,092 ▼ 54.7% | 3,973 ▲ 89.9% | 4,673 ▲ 17.6% | 5,124 ▲ 9.6% | |
| Less: Non-controlling Interests | 35 | 50 ▲ 44.2% | 28 ▼ 44.3% | 51 ▲ 84.9% | 131 ▲ 154.9% | 132 ▲ 0.5% | 3,860 ▲ 2832.8% | 4,526 ▲ 17.3% | 84 ▼ 98.2% | |
| Net Profit (Owner's PAT)Derived | 1,776 | 1,849 ▲ 4.1% | 1,177 ▼ 36.4% | 2,134 ▲ 81.3% | 4,487 ▲ 110.3% | 1,960 ▼ 56.3% | 113 ▼ 94.2% | 147 ▲ 29.8% | 5,040 ▲ 3326.2% | |
| Net Profit Margin %Derived | 14.88% | 14.04% | 8.26% | 14.13% | 29.40% | 11.37% | 0.58% | 0.63% | 18.56% | |
| PAT Growth YoY %Derived | — | 4.11% | -36.36% | 81.34% | 110.32% | -56.31% | -94.22% | 29.83% | 3,326.24% | |
| Earnings Per Share (EPS ₹) | 17.35 | 18.06 ▲ 4.1% | 11.49 ▼ 36.4% | 20.84 ▲ 81.4% | 43.83 ▲ 110.3% | 19.37 ▼ 55.8% | 1.13 ▼ 94.2% | 1.46 ▲ 29.2% | 50.09 ▲ 3330.8% | |
| Diluted Shares Outstanding (Cr) | 102 | 102 ▲ 0.0% | 102 ▲ 0.0% | 102 ▲ 0.0% | 102 ▲ 0.0% | 101 ▼ 1.1% | 101 ▼ 0.6% | 101 ▲ 0.0% | 101 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 63 | 47 ▼ 25.3% | 29 ▼ 38.6% | 47 ▲ 64.6% | 46 ▼ 2.5% | 95 ▲ 104.8% | 118 ▲ 25.2% | 58 ▼ 51.2% | 97 ▲ 68.0% | |
| Other Comprehensive Income (Net of Tax) | 20 | -168 ▼ 961.5% | -301 ▼ 78.9% | 73 ▲ 124.3% | -105 ▼ 243.0% | -314 ▼ 200.9% | -200 ▲ 36.4% | -100 ▲ 50.0% | -775 ▼ 674.8% | |
| Total Expenses (incl. D&A & Interest) | 9,719 | 10,985 ▲ 13.0% | 12,872 ▲ 17.2% | 12,855 ▼ 0.1% | 12,652 ▼ 1.6% | 14,834 ▲ 17.3% | 15,023 ▲ 1.3% | 17,484 ▲ 16.4% | 21,037 ▲ 20.3% | |
| Material Cost % of RevenueDerived | 21.40% | 20.31% | 24.27% | 25.75% | 26.48% | 23.92% | 23.43% | 18.82% | 18.82% | |
| Employee Cost % of RevenueDerived | 15.54% | 16.13% | 16.94% | 16.49% | 15.95% | 16.04% | 16.05% | 15.84% | 16.27% | |
| Other Cost % of RevenueDerived | 25.81% | 25.46% | 29.01% | 26.89% | 25.84% | 24.96% | 24.54% | 26.52% | 25.65% | |
| Interest Coverage (x)Derived | 25.34x | 12.27x | 6.11x | 16.00x | 20.69x | 24.15x | 56.90x | 37.03x | 16.10x |
ZYDUS LIFESCIENCES segment analysis : revenue and profit mix.
Disclosed business segments at ZYDUS LIFESCIENCES with their share of revenue and profit, switchable between consolidated and standalone reporting.
ZYDUS LIFESCIENCES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ZYDUS LIFESCIENCES.
Our AI distills the core fundamental drivers supporting ZYDUS LIFESCIENCES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ZYDUS LIFESCIENCES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Market cap ₹1.11 LCr ranks fourth among Indian pharma peers, strong scale.
ROCE 21.10% and ROE 21.20% exceed peer medians, superior capital efficiency.
Operating margin 21.66% outpaces peer average, pricing power evident.
P/E 22.16x trades 18% below peer median 38.97x, attractive valuation.
Promoter holding 75% ensures stable governance and long-term alignment.
Key Risks.
Latest quarterly EPS grew 8.70% YoY despite competitive pressures.
Net debt ₹20,444 Cr rising significantly, increasing leverage risk.
Operating cash flow ₹1,124 Cr in Q3 2025 down from prior periods.
Working capital swings volatile; Q3 2025 changes ₹-30,225 Cr, operational drag.
Capex intensity high at ₹8,675 Cr quarterly, constraining free cash flow.
Flip Conditions.
Valuation risk. a P/E above 33 (~0.8× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
ZYDUS LIFESCIENCES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ZYDUS LIFESCIENCES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ZYDUS LIFESCIENCES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ZYDUS LIFESCIENCES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ZYDUS LIFESCIENCES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ZYDUS LIFESCIENCES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ZYDUS LIFESCIENCES stood at 48.3% of traded volume, against a 20-day average of 51.6%.
ZYDUS LIFESCIENCES announcements: results, concalls, ratings, M&A.
Filings ZYDUS LIFESCIENCES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ZYDUS LIFESCIENCES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 330 documents below.
General Updates
Zydus Lifesciences Limited has informed the Exchange about General Updates
General Updates
Zydus Lifesciences Limited has informed the Exchange about General Updates
Press Release
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline…
General Updates
Zydus Lifesciences Limited has informed the Exchange about General Updates
General Updates
Zydus Lifesciences Limited has informed the Exchange about General Updates
Investor decks & rating reports.
ZYDUS LIFESCIENCES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ZYDUS LIFESCIENCES has declared, sequenced by announce and record date.
ZYDUS LIFESCIENCES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ZYDUS LIFESCIENCES: business, sector, key facts.
What ZYDUS LIFESCIENCES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ZYDUS LIFESCIENCES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ZYDUSLIFE, BSE: 532321.
Zydus Lifesciences Limited is a global pharmaceutical company with a diverse portfolio spanning research, development, manufacturing, marketing, and distribution of a wide range of healthcare products. Its operations extend across India, the United States, and other international markets, solidifying its position as a significant player in the industry.
The company's business is structured into two primary segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment focuses on the production and sale of finished dosage forms, including generic drugs, branded generics, and specialty formulations such as biosimilars and vaccines. They also manufacture active pharmaceutical ingredients (APIs) and cater to various therapeutic areas, encompassing pain management, neurology, metabolic disorders, and liver diseases. A strong pipeline of biological products is under development, targeting oncology, autoimmune diseases, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses.
Complementing its pharmaceutical offerings, the Consumer Products segment encompasses a portfolio of well-known brands such as Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil. These brands cater to various consumer wellness needs, demonstrating Zydus Lifesciences' commitment to holistic healthcare solutions.
Beyond its core pharmaceutical and consumer product businesses, Zydus Lifesciences also engages in other activities, including investments in related sectors, animal health and veterinary products, pharmacy retail ventures, and manpower supply and administration. This diversification strategy reflects a commitment to expanding its reach and influence within the broader healthcare ecosystem.
Founded in 1952 and headquartered in Ahmedabad, India, the company, formerly known as Cadila Healthcare Limited, rebranded to Zydus Lifesciences Limited in 2022. It operates as a subsidiary of Zydus Family Trust, reflecting its long-standing commitment to family-led stewardship and its history in the pharmaceutical industry.
Go deeper on ZYDUS LIFESCIENCES
- ZYDUS LIFESCIENCES resultsQuarter-by-quarter revenue, profit, EPS and margins for ZYDUS LIFESCIENCES.
- ZYDUS LIFESCIENCES dividendEvery dividend ZYDUS LIFESCIENCES has declared, with ex-dates and yield.
- ZYDUS LIFESCIENCES shareholdingPromoter, FII and DII holding in ZYDUS LIFESCIENCES, quarter by quarter.
- ZYDUS LIFESCIENCES financialsZYDUS LIFESCIENCES profit & loss, balance sheet and cash flow by year.
- ZYDUS LIFESCIENCES technical analysisPivots, CPR and live indicator readings for ZYDUS LIFESCIENCES.
- ZYDUS LIFESCIENCES corporate actionsBonus issues, splits, rights and buybacks declared by ZYDUS LIFESCIENCES.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ZYDUS LIFESCIENCES (ZYDUSLIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ZYDUS LIFESCIENCES (ZYDUSLIFE)?
The current share price of ZYDUS LIFESCIENCES (ZYDUSLIFE) is ₹1,120.00. Today, the stock has declined by ₹23.00 (2.01%), trading in a range of ₹1,120.00 to ₹1,146.00. The stock opened at ₹1,146.00 with a trading volume of 5,16,768 shares.
02Is ZYDUS LIFESCIENCES stock a good investment for long-term?
ZYDUS LIFESCIENCES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1.12 L Cr., P/E ratio of 25.62, ROE of 17.32%, and ROCE of 14.09%. The dividend yield stands at 0.09%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ZYDUS LIFESCIENCES stock?
The 52-week high price of ZYDUS LIFESCIENCES (ZYDUSLIFE) is ₹1,205.00, while the 52-week low is ₹835.50. Currently trading at ₹1,120.00, the stock is 34.05% above its 52-week low and 7.05% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ZYDUS LIFESCIENCES stock at the current price?
Whether to buy ZYDUS LIFESCIENCES stock at ₹1,120.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.62 and P/B ratio of 4.27. Today's performance shows a loss of 2.01%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ZYDUS LIFESCIENCES and when is the next dividend?
ZYDUS LIFESCIENCES offers a dividend yield of 0.09%, which means for every ₹100 invested at the current price of ₹1,120.00, you can expect to receive approximately ₹0.09 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ZYDUS LIFESCIENCES?
ZYDUS LIFESCIENCES's key financial metrics include: P/E Ratio: 25.62, P/B Ratio: 4.27, ROE: 17.32%, ROCE: 14.09%, Dividend Yield: 0.09%, EPS: ₹9.42, Book Value: ₹296.56, and Debt-to-Equity: 0.4. The company's market cap stands at ₹1.12 L Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ZYDUS LIFESCIENCES stock performing today in the market?
ZYDUS LIFESCIENCES stock opened at ₹1,146.00 and is currently trading at ₹1,120.00, showing a decline of ₹23.00 (2.01%). The intraday high is ₹1,146.00 and low is ₹1,120.00. The trading volume stands at 5,16,768 shares, indicating moderate market participation today.
08What is the P/E ratio of ZYDUS LIFESCIENCES and what does it indicate?
ZYDUS LIFESCIENCES has a Price-to-Earnings (P/E) ratio of 25.62, which means investors are willing to pay 25.62 for every ₹1 of earnings. With an EPS of ₹9.42, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ZYDUS LIFESCIENCES (ZYDUSLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.